EichorEICHOR
Location: Plantation Synced from ClinicalTrials.gov · August 07, 2026

Clinical studies recruiting near Plantation

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS
NA · Comprehensive Medical & Research Center · Philip Morris Products S.A. · NCT07108166This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in
Phase 3 · BRCR Global · Pfizer · NCT06758401A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
Phase 3 · IRIS Research and Development | Plantation, FL · Takeda · NCT06671496Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
Phase 3 · Clinical Study Site · Summit Therapeutics · NCT07228832Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astr
Phase 1 · UM Sylvester Comprehensive Cancer Center at Plantation · National Cancer Institute (NCI) · NCT06860594A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathie
Phase 3 · IRIS Research and Development, LLC · Pfizer · NCT05895786ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer
Phase 2 · BRCR Global · Zenith Epigenetics · NCT04986423DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refrac
Phase 2 · BRCR Medical Center Inc. · ImmunoVaccine Technologies, Inc. (IMV Inc.) · NCT04920617A Study of IBI363 in Subjects with Advanced Solid Malignancies
Phase 2 · BRCR Medical Center · Innovent Biologics (Suzhou) Co. Ltd. · NCT06281678A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain
Phase 2 · Martin E. Hale M.D., P.A. · Eli Lilly and Company · NCT05986292A Study to Assess Safety and Tolerability of PCRX-201 in Subjects With Painful Osteoarthritis of the Knee
Phase 2 · Discovery Health Research Center - Plantation, FL · Pacira Pharmaceuticals, Inc · NCT06884865Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-
Phase 3 · UM Sylvester Comprehensive Cancer Center at Plantation · NRG Oncology · NCT06500481A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants Wi
Phase 1 · Florida Clinical Trials Group · IDEAYA Biosciences · NCT07540572ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathol
Phase 3 · UM Sylvester Comprehensive Cancer Center at Plantation · Alliance for Clinical Trials in Oncology · NCT06876714A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice
Phase N/A · Edward Jenner Research Group, LLC - Site Number: 840169 · Sanofi · NCT07556159A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
Phase 1/Phase 2 · Nkarta Investigational Site · Nkarta, Inc. · NCT06733935Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or
Phase 3 · UM Sylvester Comprehensive Cancer Center at Plantation · Canadian Cancer Trials Group · NCT03550391BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer
Phase 3 · Florida Clinical Trials Group Plantation · BeOne Medicines · NCT07492641Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and S
Phase 3 · UM Sylvester Comprehensive Cancer Center at Plantation · Canadian Cancer Trials Group · NCT06592924A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H
Phase 2/Phase 3 · Comprehensive Medical & Research Center /ID# 261678 · AbbVie · NCT06345339An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Phase 3 · Research Site · AstraZeneca · NCT05952557Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely
Phase 3 · UM Sylvester Comprehensive Cancer Center at Plantation · NRG Oncology · NCT03180268Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Deg
Phase 3 · Adverum Clinical Site 206 · Adverum Biotechnologies, Inc. · NCT07482176Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metas
Phase 2 · UM Sylvester Comprehensive Cancer Center at Plantation · National Cancer Institute (NCI) · NCT03606967Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIR
Phase 3 · IRIS Research and Development · Novartis Pharmaceuticals · NCT06133972A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Sub
Phase 1 · Discovery Health Research Center /ID# 279691 · AbbVie · NCT07607964OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
Phase 3 · Clinical Trial Site · Olema Pharmaceuticals, Inc. · NCT06016738Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Phase 3 · BRCR Global · Revolution Medicines, Inc. · NCT06881784Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer
Phase 3 · UM Sylvester Comprehensive Cancer Center at Plantation · NRG Oncology · NCT05646316R-3750 in Patients With Mild to Moderate Ulcerative Colitis
Phase 1 · Edward Jenner Research Group, LLC · Rise Therapeutics LLC · NCT05666960
Look up another city
Look up another condition
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.